Cagrilintide

01 · What is it?

The identity comes first.

Cagrilintide is designed to mimic aspects of amylin, a hormone released with insulin after meals. It is studied alone and with semaglutide in CagriSema. Evidence for the combination must be distinguished from cagrilintide alone.

Scientific classification: Investigational long-acting amylin peptide analogue

For example. It resembles an extended meal-completion message rather than an insulin replacement.

02 · How does it work?

The signal, explained.

It copies aspects of the after-meal amylin message. The research focuses on how receiving circuits in the brain respond and how those responses relate to eating and glucose regulation.

The key research focus is Amylin receptors (calcitonin receptor + RAMP proteins). A target describes where an interaction may occur; it does not by itself establish a benefit.

03 · What happens after the signal?

Follow the downstream effects.

Hindbrain pathways, including the area postrema, participate in satiety signaling. Gastric-emptying and glucagon-related effects contribute to amylin physiology; each effect needs compound-specific evidence.

To connect this mechanism to a real-world outcome, researchers need to establish exposure at the target, measure the response and test whether the change matters in a controlled human study.

04 · What is it commonly researched for?

The questions researchers are asking.

Researchers have investigated appetite, body weight and glycemic outcomes, including the cagrilintide/semaglutide combination.

These are areas of investigation, not promises about a Maison product.

05 · Body systems involved

Where the biology connects.

Brain

Relevant to neural signaling, appetite, behavior or stress circuitry described above.

Digestive tract

Relevant to secretion, motility, epithelial transport or gut–brain signaling.

Pancreas

Participates in insulin, glucagon and meal-related hormone signaling.

06 · Receptor / target profile

The molecular reference card.

Primary receptor or target

Amylin receptors (calcitonin receptor + RAMP proteins)

Secondary interactions

Calcitonin-receptor activity is relevant to its pharmacologic profile.

Where it is found

Hindbrain satiety networks; distribution and response vary by receptor subtype.

Activation, inhibition or interaction

Amylin receptors are complexes of the calcitonin receptor with receptor activity-modifying proteins. Cagrilintide has amylin and calcitonin receptor pharmacology; receptor-subtype selectivity differs from eloralintide.

Important downstream pathways

Hindbrain pathways, including the area postrema, participate in satiety signaling. Gastric-emptying and glucagon-related effects contribute to amylin physiology; each effect needs compound-specific evidence.

07 · Evidence quality

What carries weight—and what does not.

A familiar mechanism, a patent, a testimonial or a trial registration alone cannot establish human efficacy or product quality.

08 · Who is studying it?

Follow the original research.

Novo Nordisk

Program: CagriSema: REDEFINE (weight-management research) and REIMAGINE (type 2 diabetes research)

Development phase: Phase 3 CagriSema programs; do not apply this phase to every standalone cagrilintide study.

Example trial record: NCT05567796

Regulatory context: Sponsor sources describe investigational clinical development and a CagriSema FDA submission in December 2025. Submission is not approval; check the current registry and regulator for subsequent decisions.

Registry links may include related compounds or historical studies. Read the exact intervention, sponsor, phase and latest update date. Recruitment status is specific to each trial.

09 · Research terminology

A small glossary for this page.

Explore the complete foundations glossary

10 · Research status & limitations

Keep the boundaries visible.

Sponsor sources describe investigational clinical development and a CagriSema FDA submission in December 2025. Submission is not approval; check the current registry and regulator for subsequent decisions.

Long-term outcomes, comparative benefit, clinically meaningful effects and safety for broad wellness use are not well established.

The main evidence category here is human clinical research. The exact molecule, formulation, study population and endpoint matter. Scientific evidence changes; this page is a dated educational summary, not continuous trial monitoring.